Axsome Therapeutics, Inc (AXSM) Stock Price

AXSMStock

$157.14+25.71%52W

Market Cap$8.23B

P/E—

PEG Ratio—

Div yield—

Beta0.82

AXSM Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-24.59%

Price vs S&P 500 (4W)-22.20%

VGM Score53.09

Book Value / Share (Quarterly)$1.59

P/TBV (Annual)410.04x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)133.68%

Cash Flow / Share (Quarterly)$-1.38

Price vs S&P 500 (YTD)-25.89%

Gross Margin (TTM)93.24%

Net Profit Margin (TTM)-24.68%

EPS (TTM)$-3.76

10-Day Avg Trading Volume0.96M

EPS Excl Extra (TTM)$-3.76

EPS (Annual)$-3.68

ROI (Annual)-118.68%

Gross Margin (Annual)92.56%

Net Profit Margin (5Y Avg)-1038.72%

Cash / Share (Quarterly)$6.12

Revenue Growth QoQ (YoY)45.54%

ROA (Last FY)-50.57%

Revenue Growth TTM (YoY)56.87%

EBITD / Share (TTM)$-3.53

ROE (5Y Avg)-345.24%

Operating Margin (TTM)-23.96%

Cash Flow / Share (Annual)$-2.63

P/B Ratio98.81x

P/B Ratio (Quarterly)151.20x

Net Income / Employee (Annual)$-198,000

EV / Revenue (TTM)10.45x

Net Interest Coverage (TTM)-27.02x

ROA (TTM)-27.05%

EPS Incl Extra (Annual)$-3.68

Current Ratio (Annual)2.11x

Quick Ratio (Quarterly)1.30x

3-Month Avg Trading Volume0.84M

52-Week Price Return25.71%

Revenue / Employee (TTM)$839,500

Tangible BV / Share (Quarterly)$0.88

P/S Ratio (Annual)12.89x

Asset Turnover (Annual)0.68x

52-Week High$260.19

Operating Margin (5Y Avg)-1009.22%

EPS Excl Extra (Annual)$-3.68

CapEx CAGR (5Y)57.20%

Tangible BV CAGR (5Y)18.82%

26-Week Price Return-14.68%

Quick Ratio (Annual)1.99x

13-Week Price Return-31.68%

Total Debt / Equity (Annual)3.25x

Current Ratio (Quarterly)1.43x

Enterprise Value$8.11B

Asset Turnover (TTM)1.10x

Book Value / Share Growth (5Y)-24.82%

Revenue / Employee (Annual)$690,300

Pretax Margin (Annual)-28.77%

Cash / Share (Annual)$6.43

3-Month Return Std Dev40.36%

Net Income / Employee (TTM)$-207,200

ROE (Last FY)-503.89%

Net Interest Coverage (Annual)-37.09x

EPS Basic Excl Extra (Annual)$-3.68

Receivables Turnover (TTM)3.26x

Total Debt / Equity (Quarterly)2.43x

EPS Incl Extra (TTM)$-3.76

ROI (TTM)-70.42%

P/S Ratio (TTM)10.60x

Pretax Margin (5Y Avg)-1038.72%

Revenue / Share (Annual)$12.83

Tangible BV / Share (Annual)$0.20

Forward P/E63.03x

Price vs S&P 500 (52W)10.18%

Year-to-Date Return-13.96%

5-Day Price Return-5.34%

EPS Normalized (Annual)$-3.68

ROA (5Y Avg)-70.30%

Net Profit Margin (Annual)-28.69%

Month-to-Date Return-14.78%

Cash Flow / Share (TTM)$-4.39

EBITD / Share (Annual)$-3.43

Operating Margin (Annual)-27.74%

LT Debt / Equity (Annual)0.93x

ROI (5Y Avg)-108.06%

LT Debt / Equity (Quarterly)1.42x

EPS Basic Excl Extra (TTM)$-3.76

P/TBV (Quarterly)274.14x

P/B Ratio (Annual)71.94x

Inventory Turnover (TTM)1.87x

Pretax Margin (TTM)-24.61%

Book Value / Share (Annual)$1.16

Price vs S&P 500 (13W)-34.36%

Beta0.82x

Revenue / Share (TTM)$14.99

ROE (TTM)-255.60%

52-Week Low$123.50

vGradeD

gGradeB

mGradeC

vgmGradeC

AXSM Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 10, 2026	-$0.78	-$0.99	-26.85%(-$0.21)
Q1 2026	May 4, 2026	-$0.86	-$1.26	-46.03%(-$0.40)
Q4 2025	Feb 23, 2026	-$0.73	-$0.56	+23.63%(+$0.17)
Q3 2025	Nov 3, 2025	-$0.90	-$0.94	-4.19%(-$0.04)
Q2 2025	Aug 4, 2025	-$1.09	-$0.97	+10.75%(+$0.12)

AXSM Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.30

4.29

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78
MIRMMirum Pharmaceuticals, Inc. Common Stock	F	B	C	8.4x	44.0%	81.7%	—	$80.14

About Axsome Therapeutics, Inc

Axsome Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system disorders with limited existing treatment options. The company's pipeline includes four late-stage candidates: AXS-05, AXS-07, AXS-12, and AXS-14, addressing multiple indications in neurology and psychiatry. Axsome targets underserved patient populations where unmet medical needs remain high.

AXSM Next Earnings Report

Report dateNov 2, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate-$0.63

Revenue estimate$250.91M

Also reporting on Nov 2, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

AXSM Insider Transactions

SellSep 3, 2026
JACOBSON MARK L
Chief Operating Officer
Shares: 10,000Value: $2.09M
SellAug 6, 2026
TABUTEAU HERRIOT
Chief Executive Officer
Shares: 49,664Value: $10.54M

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

KRYSKrystal Biotech, Inc. Common StockBiological Products
TWSTTwist Bioscience Corporation Common StockBiological Products
KYMRKymera Therapeutics, Inc. Common StockBiological Products
ESIElement Solutions Inc.Industrial Chemicals
WLKWestlake CorporationIndustrial Chemicals
NEUNewMarket CorporationIndustrial Chemicals
AXTAAxalta Coating Systems Ltd.Paints & Coatings
EMNEastman Chemical CompanyPlastics & Resins

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$123.50

High$260.19